Mirum Historical Cash Flow
| MIRM Stock | USD 51.50 1.57 3.14% |
Analysis of Mirum Pharmaceuticals cash flow over time is an excellent tool to project Mirum Pharmaceuticals future capital expenditures as well as to predict the amount of cash needed to cover cost of sales, R&D expenses or production expansions. Investors should almost always look for trends in cash flow indicators such as Exchange Rate Changes of 0.0 or Depreciation of 13.1 M as it is a great indicator of Mirum Pharmaceuticals ability to facilitate future growth, repay debt on time or pay out dividends.
Financial Statement Analysis is much more than just reviewing and examining Mirum Pharmaceuticals latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Mirum Pharmaceuticals is a good buy for the upcoming year.
Mirum |
About Mirum Cash Flow Analysis
The Cash Flow Statement is a financial statement that shows how changes in Mirum balance sheet and income statement accounts affect cash and cash equivalents. It breaks the analysis down to operating, investing, and financing activities. One of the most critical aspects of the cash flow statement is liquidity, which is the degree to which Mirum's non-liquid assets can be easily converted into cash.
Mirum Pharmaceuticals Cash Flow Chart
Add Fundamental
Capital Expenditures
Capital Expenditures are funds used by Mirum Pharmaceuticals to acquire physical assets such as property, industrial buildings or equipment. This type of outlay is used by management to increase the scope of Mirum Pharmaceuticals operations. These expenditures can include everything from repairing an office equipment, building a brand new facility, or writing new software.Most accounts from Mirum Pharmaceuticals' cash flow statement are interrelated and interconnected. However, analyzing cash flow statement accounts one by one will only give a small insight into Mirum Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of cash flow statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Mirum Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. To learn how to invest in Mirum Stock, please use our How to Invest in Mirum Pharmaceuticals guide.At this time, Mirum Pharmaceuticals' Change To Liabilities is very stable compared to the past year. As of the 26th of February 2025, Other Non Cash Items is likely to grow to about 83.6 M, though Change To Inventory is likely to grow to (3.8 M).
| 2021 | 2022 | 2024 | 2025 (projected) | Change To Liabilities | 22.7M | 7.6M | 8.8M | 10.5M | Change To Netincome | 23.1M | 27.0M | 31.1M | 19.8M |
Mirum Pharmaceuticals cash flow statement Correlations
Click cells to compare fundamentals
Mirum Pharmaceuticals Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Mirum Pharmaceuticals cash flow statement Accounts
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Sale Purchase Of Stock | 127.2M | 131.9M | 9.0M | 15.6M | 14.0M | 13.3M | |
| Investments | 11.3M | (42.4M) | 8.0M | (78.4M) | (90.2M) | (94.7M) | |
| Change In Cash | 130.1M | (10.7M) | (3.3M) | 158.3M | 182.1M | 191.2M | |
| Total Cashflows From Investing Activities | (127.8M) | 37.9M | 48.5M | 7.7M | 8.9M | 9.3M | |
| Depreciation | 623K | 975K | 3.7M | 10.8M | 12.5M | 13.1M | |
| Capital Expenditures | 225K | 19.0M | 278K | 20.1M | 23.1M | 24.3M | |
| Total Cash From Operating Activities | (89.1M) | (132.8M) | (120.1M) | (70.9M) | (63.8M) | (67.0M) | |
| Change To Operating Activities | (2.9M) | (3.1M) | (5.2M) | (4.5M) | (4.1M) | (4.3M) | |
| Net Income | (103.3M) | (84.0M) | (135.7M) | (163.4M) | (147.1M) | (154.4M) | |
| Total Cash From Financing Activities | 181.3M | 73.5M | 109.1M | 336.6M | 387.1M | 406.4M | |
| End Period Cash Flow | 142.1M | 131.3M | 128.0M | 286.3M | 329.3M | 345.7M | |
| Other Cashflows From Investing Activities | 38.1M | 127M | 8.0M | (20M) | (18M) | (17.1M) | |
| Change To Netincome | 5.7M | 12.6M | 23.1M | 27.0M | 31.1M | 19.8M | |
| Change To Liabilities | 10.1M | 3.7M | 22.7M | 7.6M | 8.8M | 10.5M | |
| Stock Based Compensation | 12.6M | 23.1M | 27.0M | 35.0M | 40.3M | 22.8M | |
| Free Cash Flow | (89.3M) | (151.8M) | (120.4M) | (91.1M) | (81.9M) | (86.0M) | |
| Change In Working Capital | 611K | 17.0M | (21.1M) | (22.6M) | (20.4M) | (19.4M) | |
| Begin Period Cash Flow | 12.0M | 142.1M | 131.3M | 128.0M | 147.2M | 102.4M | |
| Other Non Cash Items | 335K | (90.4M) | 12.5M | 69.3M | 79.6M | 83.6M | |
| Issuance Of Capital Stock | 131.9M | 9.0M | 107.4M | 216.6M | 249.0M | 130.2M |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Mirum Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. To learn how to invest in Mirum Stock, please use our How to Invest in Mirum Pharmaceuticals guide.You can also try the Portfolio Optimization module to compute new portfolio that will generate highest expected return given your specified tolerance for risk.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Mirum Pharmaceuticals. If investors know Mirum will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Mirum Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.08) | Revenue Per Share | Quarterly Revenue Growth 0.894 | Return On Assets | Return On Equity |
The market value of Mirum Pharmaceuticals is measured differently than its book value, which is the value of Mirum that is recorded on the company's balance sheet. Investors also form their own opinion of Mirum Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Mirum Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Mirum Pharmaceuticals' market value can be influenced by many factors that don't directly affect Mirum Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Mirum Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Mirum Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Mirum Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.